Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 246 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Woman Finds Out She Has Breast Cancer From Museum Photo Booth November 1, 2019 Cancer Research UK publishes gender and ethnicity pay gap reports January 20, 2022 How Can Hormone Replacement Therapy for Menopause Impact My Cancer Risk? January 4, 2023 Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... June 21, 2023 Load more HOT NEWS Qué debe saber sobre las pruebas de ADN en el hogar... Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at... Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two...
